Yüklüyor......
Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
Immune tolerance induction (ITI) with a short-course of rituximab, methotrexate, and/or IVIG in the enzyme replacement therapy (ERT)-naïve setting has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD) lacking endogenous acid-alpha glucosidase (GAA), kno...
Kaydedildi:
| Yayımlandı: | Front Immunol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7424004/ https://ncbi.nlm.nih.gov/pubmed/32849613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01727 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|